YANG Qing,YOU Ze-Shan. Active immunotherapy for women with unexplained recurrent spontaneous abortion: a follow-up study on growth and development of offspring[J]. CJCP, 2011, 13(11): 926-928.
［1］American College of Obstetricians and Gynecologists. ACOG practice bulletin: management of recurrent early pregnancy loss. Number 24, February 2001［J］. Int Gynecol Obstet, 2002,78(2): 179-190.
［2］Li TC, Makris M, Tomsu M, Tuckerman E, Laird S. Recurrent miscarriage: aetiology, management and prognosis［J］. Hum Reprod Update, 2002, 8(5): 463-481.
［7］Needlman RD. Growth and development［M］//Behrman RE, Kileman RM, Jenson HB. Nelson textbook of pediatrics.16th ed. Philadelphia: Saunders Company, 2000: 23.
［8］Petr-nyi GG, Réti M, Hars-nyi V, Szab-J. Immunologic consequences of blood transfusion and their clinical manifestations［J］. Int Arch Allergy Immunol, 1997, 114（4）: 303-315.
［9］Tanaka T, Umesaki N, Nishio J, Maeda K, Kawamura T, Araki N, et al. Neonatal thrombocytopenia induced by maternal antiHLA antibodies: a potential side effect of allogenic leukocyte immunization for unexplained recurrent aborters［J］. J Reprod Immunol, 2000, 46(1): 51-57.
［10］Reginald PW, Beard RW, Chapple J, Forbes PB, Liddell HS, Mowbray JF, et al. Outcome of pregnancies progressing beyond 28 weeks gestation in women with a history of recurrent miscarriage［J］. Br J Obstet Gynecol, 1987, 94(7): 643-648.
［13］Sheiner E, Levy A, Katz M, Mazor M. Pregnancy outcome following recurrent spontaneous abortions［J］. Europ J Obstet Gynecol Reprod Biol, 2005, 118(1): 61-65.
